Introducing Tempo: A Connected Insulin Pen to Simplify Diabetes Management - Industry Symposium Supported by Eli Lilly

Session description - This symposium will introduce Tempo™, a Personalized Diabetes Management System from Eli Lilly, that integrates insulin dosing data with technology to help simplify diabetes management.   Digital health technologies can help improve patient data visibility, physician-patient collaboration, clinical decision-making, and patient self-management, ultimately leading to better outcomes.   Faculty will discuss the complexities of insulin management, and how insulin dosing data may help facilitate communication between you and the people you treat.  Automating insulin dosing data may help:  

• Gain an understanding of their management patterns

• Stay informed between office visits

• Feel empowered to engage in shared decision-making

The Tempo Smart Button™ (pending CE mark) attaches to a Tempo Pen™ prefilled with Abasaglar, Humalog, or Lyumjev insulin.  Data from the Tempo System will integrate with commercially available software. The Tempo Smart Button is intended to reliably store and transmit insulin dosing data to a compatible app.  Tempo provides a comprehensive view of how people manage their insulin day-to-day.  Adding insulin dosing data to other data related to your patients’ insulin therapy (e.g., blood glucose, carbohydrate intake) may help inform treatment decisions. This program is for all healthcare professionals treating people with diabetes on multiple daily injections of mealtime insulin.

The materials for Tempo Pen™ contained in this virtual symposium are approved for use only in EU and UK. The Tempo Smart Button™ is pending CE mark. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).